News

Hennigsdorf/Berlin (Germany), August 30th, 2021 – Adrenomed AG, the vascular integrity company, announced today its participation in four upcoming scientific and industry events. Adrenomed representatives will be available for networking and one-on-one meetings at the

Adrenomed supports the #DeutschlandErkenntSepsis campaign initiated by Aktionsbündnis Patientensicherheit and supported by Sepsis Stiftung, Sepsisdialog and Deutsche Sepsis-Hilfe. The campaign’s goal is to raises awareness of sepsis and to improve recognition, diagnosis, and treatment of

Former CEO of Boehringer Ingelheim USA Corp. to accelerate Adrenomed’s development of Adrecizumab in septic shock Hennigsdorf/Berlin (Germany), January 04, 2021 – Adrenomed AG, the vascular integrity company, announced today that its Supervisory Board has

Treatment of septic shock patients with Adrecizumab resulted in significant and sustained mortality reduction most pronounced in early treated patients Adrecizumab, a product candidate for personalized treatment of septic shock, addresses loss of vascular integrity,

Series E round led by existing top-tier life science investors Wellington Partners and HBM Healthcare Investments Data from AdrenOSS-2 on early treatment start with Adrecizumab in septic shock to be presented at DIVI, December 2-4,

Primary endpoint of AdrenOSS-2 achieved: Adrecizumab was well tolerated and showed a favorable safety profile In this biomarker-guided trial, Adrecizumab demonstrated significant and fast improvement of organ function and a substantial reduction on short-term mortality

Hennigsdorf/Berlin (Germany), September 14, 2020 – Adrenomed AG, the vascular integrity company, announced today that data from the AdrenOSS-2 Phase II clinical trial with Adrecizumab in septic shock (NCT03085758[i]) will be presented during the International

Adrecizumab (HAM8101) showed a favourable outcome in a case series of eight COVID‐19 patients with life-threatening organ failure in ICU At publication, this represented the first data evaluating an experimental therapy in such late-stage COVID-19

The meeting “Global Burden, Diagnosis, and Adjunctive Therapies of Sepsis and COVID-19” will be available via livestream today, March 16, at 5:00 pm CET Adrenomed recently announced positive topline data from its AdrenOSS-2 Phase II

Adrecizumab, given on top of standard of care, was well tolerated and showed a favorable safety profile Adrecizumab demonstrates a positive trend on survival AdrenOSS-2 is a biomarker-guided (sphingotest bio-ADM®[1]) trial in sepsis Mode of